Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer (Q38319226)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

2 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer (English)

1 reference

2 September 2017

1 reference

Annavarapu Srinivas Rao

1

1 reference

2 September 2017

Natalia Kremenevskaja

2

1 reference

2 September 2017

Reinhard von Wasielewski

3

1 reference

2 September 2017

Vladimira Jakubcakova

4

1 reference

2 September 2017

Shashi Kant

5

1 reference

2 September 2017

Julia Resch

6

1 reference

2 September 2017

Georg Brabant

7

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

The Journal of Clinical Endocrinology and Metabolism

2 September 2017

1 reference

2 September 2017

91

1 reference

2 September 2017

1

1 reference

2 September 2017

159-168

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

2 September 2017

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Identification of a Wnt/beta-catenin signaling pathway in human thyroid cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Tyrosine phosphorylation and src family kinases control keratinocyte cell-cell adhesion.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Wnt-5a has tumor suppressor activity in thyroid carcinoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Clinical significance of E-cadherin expression in thyroid neoplasms

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Nuclear accumulation of full-length and truncated adenomatous polyposis coli protein in tumor cells depends on proliferation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

The significance of the Wnt pathway in the pathology of human cancers

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

STI571: targeting BCR-ABL as therapy for CML.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Expression of the cadherin-catenin complex in well-differentiated human thyroid neoplastic tissue

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Cycling, stressed-out and nervous: cellular functions of c-Abl

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1210/JC.2005-1381

Identifiers

DOI

10.1210/JC.2005-1381

1 reference

2 September 2017

1 reference